神经科

订阅

MedSci主页 / 所有栏目 / 神经科

病人出现异动症后怎么减少美多芭？

2021-07-15 MedSci原创 MedSci原创

心律失常异动症
关注

病人出现异动症后怎么减少美多芭？-第十个问题

《梅斯直播课：心律失常的临床诊断与心电图分析 》

回答问题10：帕金森病人自行加量美多芭后出现异动症后怎么减少美多芭？

 

欢迎点赞、评论、分享

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1000199, encodeId=d1e110001995d, content=谢谢 学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f221859736, createdName=ms2658711348342440, createdTime=Fri Jul 16 22:03:06 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999873, encodeId=508d9998e3d1, content=学习了，好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210121/12caa033f74041d6b37583b6335ef7ef/2d50613dd3014bfd9e2b7ad59ceba53a.jpg, createdBy=0c8f5324907, createdName=Bunnymeng, createdTime=Thu Jul 15 22:34:23 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999761, encodeId=334d999e61e1, content=学习了 谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210901/969603a2377544169c0528539edd5ab7/50bbe992202d43569f6cc40d89829e36.jpg, createdBy=b54c5537441, createdName=智慧药, createdTime=Thu Jul 15 14:45:48 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999759, encodeId=f781999e59a7, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210901/969603a2377544169c0528539edd5ab7/50bbe992202d43569f6cc40d89829e36.jpg, createdBy=b54c5537441, createdName=智慧药, createdTime=Thu Jul 15 14:44:34 CST 2021, time=2021-07-15, status=1, ipAttribution=)]
    2021-07-16 ms2658711348342440

    谢谢 学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1000199, encodeId=d1e110001995d, content=谢谢 学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f221859736, createdName=ms2658711348342440, createdTime=Fri Jul 16 22:03:06 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999873, encodeId=508d9998e3d1, content=学习了，好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210121/12caa033f74041d6b37583b6335ef7ef/2d50613dd3014bfd9e2b7ad59ceba53a.jpg, createdBy=0c8f5324907, createdName=Bunnymeng, createdTime=Thu Jul 15 22:34:23 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999761, encodeId=334d999e61e1, content=学习了 谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210901/969603a2377544169c0528539edd5ab7/50bbe992202d43569f6cc40d89829e36.jpg, createdBy=b54c5537441, createdName=智慧药, createdTime=Thu Jul 15 14:45:48 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999759, encodeId=f781999e59a7, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210901/969603a2377544169c0528539edd5ab7/50bbe992202d43569f6cc40d89829e36.jpg, createdBy=b54c5537441, createdName=智慧药, createdTime=Thu Jul 15 14:44:34 CST 2021, time=2021-07-15, status=1, ipAttribution=)]
    2021-07-15 Bunnymeng

    学习了，好文章

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1000199, encodeId=d1e110001995d, content=谢谢 学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f221859736, createdName=ms2658711348342440, createdTime=Fri Jul 16 22:03:06 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999873, encodeId=508d9998e3d1, content=学习了，好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210121/12caa033f74041d6b37583b6335ef7ef/2d50613dd3014bfd9e2b7ad59ceba53a.jpg, createdBy=0c8f5324907, createdName=Bunnymeng, createdTime=Thu Jul 15 22:34:23 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999761, encodeId=334d999e61e1, content=学习了 谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210901/969603a2377544169c0528539edd5ab7/50bbe992202d43569f6cc40d89829e36.jpg, createdBy=b54c5537441, createdName=智慧药, createdTime=Thu Jul 15 14:45:48 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999759, encodeId=f781999e59a7, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210901/969603a2377544169c0528539edd5ab7/50bbe992202d43569f6cc40d89829e36.jpg, createdBy=b54c5537441, createdName=智慧药, createdTime=Thu Jul 15 14:44:34 CST 2021, time=2021-07-15, status=1, ipAttribution=)]
    2021-07-15 智慧药

    学习了 谢谢

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1000199, encodeId=d1e110001995d, content=谢谢 学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f221859736, createdName=ms2658711348342440, createdTime=Fri Jul 16 22:03:06 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999873, encodeId=508d9998e3d1, content=学习了，好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210121/12caa033f74041d6b37583b6335ef7ef/2d50613dd3014bfd9e2b7ad59ceba53a.jpg, createdBy=0c8f5324907, createdName=Bunnymeng, createdTime=Thu Jul 15 22:34:23 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999761, encodeId=334d999e61e1, content=学习了 谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210901/969603a2377544169c0528539edd5ab7/50bbe992202d43569f6cc40d89829e36.jpg, createdBy=b54c5537441, createdName=智慧药, createdTime=Thu Jul 15 14:45:48 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999759, encodeId=f781999e59a7, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210901/969603a2377544169c0528539edd5ab7/50bbe992202d43569f6cc40d89829e36.jpg, createdBy=b54c5537441, createdName=智慧药, createdTime=Thu Jul 15 14:44:34 CST 2021, time=2021-07-15, status=1, ipAttribution=)]
    2021-07-15 智慧药

    学习了

    0

相关资讯

JACC：改良的非缺血扩张型心肌病患者室性心律失常和猝死风险分层

改良的非缺血扩张型心肌病患者室性心律失常和猝死风险分层

直播预告：瑞金医院刘霞主任：心律失常的临床诊断与心电图分析

6月28日晚19:00开课 | 课程形式：直播分享+问答互动+纸质书抽送

Eur J Endocrinol：急性低血糖对2型糖尿病患者心律失常风险的影响

对于采用胰岛素治疗的2型糖尿病患者和没有糖尿病的健康对照个体，低血糖均可诱发临床显著的相似的心脏复极增强，这可能会增加严重心律失常和心源性猝死的易感性

JACC：影响复苏抢救过的心脏骤停患者生存率的因素

心律失常原因、室性心动过速/纤颤初始节律和白种人都是复苏性心脏骤停患者存活的独立预测因素

心律失常如何合理制定更优的治疗方案？

如何合理制定最优的治疗方案？

快速心律失常心电图有没有简便的识别方式？

快速心律失常心电图有没有简便的识别方式？

拓展阅读

图解什么是左旋多巴所致的异动症

帕金森病患者长期服用左旋多巴后可能出现异动症。

The Lancet：帕金森病临床诊治七大要点

帕金森病（PD）是仅次于阿尔茨海默病的第二大神经退行性疾病，目前认为其是一种累及多系统的复杂性神经系统疾病。

以发作性憋气伴低氧血症为异动症表现的帕金森病一例

帕金森药源性异动症（L-dopa-induced dyskinesia，LID）为左旋多巴治疗后常见并发症，临床表现复杂。现将我院1例确诊LID误诊为癫痫的患者临床诊治经过报道如下。